FDA hearing examines safeguards for potential psychedelic mental health treatments

On Sep. 14, 2026, the FDA held a public hearing on safeguards for potential supervised use of psychedelic drugs such as psilocybin and MDMA-related compounds for serious mental-health conditions, including treatment-resistant depression and PTSD. The session was not an approval decision. It examined patient screening, provider training, clinical monitoring, clinic capacity, reimbursement and long-term safety tracking. Dozens of clinicians, advocates, researchers and investors made pitches on rollout. NPR’s Will Stone reported from the hearing with host Juana Summers. What speakers contested was how tight the rules should be at the start. Hospice physician Lida Fatemi said these are not medications doctors simply prescribe and dispense, because psychedelic care touches perception, memory, identity and profound vulnerable territory, and she pressed specialized provider training. Johns Hopkins researcher Edward Jacobs argued it is better to start with stronger protections and adjust them as evidence accumulates than to start weaker and tighten after harm. NPR described clear tension over the restrictions the FDA may set. Treatments are generally given in controlled settings with supervision, not at home. The Trump administration has signaled support through regulatory coordination, priority vouchers, potential Right to Try pathways and collaboration with the Department of Veterans Affairs. President Trump recently signed an executive order on psychedelics, and Health Secretary Robert F. Kennedy Jr. has repeatedly said he wants these drugs approved. FDA has approved only ketamine so far among psychoactive drugs for treatment use. Compass says it could launch a synthetic psilocybin product as soon as next year if it wins approval. Analysts and industry officials see potential approvals as early as 2027.